Avenge Bio
Latest round
- Series A
Last raised
- Dec 2021
Total raised
- $46M
Investors
- 5
About Avenge Bio
Based in Massachusetts, US, and founded in 2019 by CEO Michael Heffernan and co-founders Dr. Omid Veiseh and Dr. Paul K. Wotton, Avenge Bio is a biotechnology company that develops an immunotherapy platform intended to treat cancer. Avenge Bio develops the LOCOcyteTM immunotherapy platform for the precise delivery of potent immune effector molecules for the treatment of solid tumors. The LOCOcyteTM platform leverages proprietary engineered cells delivered to the local tumor environment to generate high concentrations of immune effector molecules in proximity to the tumor.
Who invested in Avenge Bio
5 investors across 1 round
See all investors in Avenge Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Dec 21, 2021
Amount
$46M
Investors
Questions about Avenge Bio
Who invested in Avenge Bio?
Avenge Bio has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Avenge Bio raised?
Avenge Bio has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Avenge Bio last raise money?
Avenge Bio's most recent round on record is a Series A, in Dec 2021.
What does Avenge Bio do?
Based in Massachusetts, US, and founded in 2019 by CEO Michael Heffernan and co-founders Dr.
Where is Avenge Bio headquartered?
Avenge Bio is headquartered in Cambridge, US.
Which VCs invest in companies like Avenge Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Kleiner Perkins and Lightspeed Venture Partners back healthcare companies at Avenge Bio's stage. Their profiles are linked below.
VCs backing healthcare startups at Series A
Raising like Avenge Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.